Investment Fund for Scotland and Macmillan Back Dxcover in £5M Growth Round
February 17, 2025
Dxcover, a University of Strathclyde spin-out developing multiomic, AI-enabled liquid biopsy diagnostics, raised £5 million from new and existing investors including the Investment Fund for Scotland (managed by Maven), Macmillan Cancer Support, Eos Advisory (lead), SIS Ventures, the University of Strathclyde and Norcliffe Capital. The funding will advance Dxcover's PANAROMIC platform technology, accelerate commercialisation of its brain cancer liquid biopsy and support expansion into the UK, Europe and the United States.
- Buyers
- Investment Fund for Scotland (IFS) / Maven, Macmillan Cancer Support, Eos Advisory, SIS Ventures, University of Strathclyde, Norcliffe Capital
- Targets
- Dxcover
- Industry
- Biotechnology
- Location
- Scotland, United Kingdom
- Transaction Type
- Growth capital
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.